Nurexone Biologic Stock Net Income

NRX Stock   0.71  0.01  1.43%   
NurExone Biologic fundamentals help investors to digest information that contributes to NurExone Biologic's financial success or failures. It also enables traders to predict the movement of NurExone Stock. The fundamental analysis module provides a way to measure NurExone Biologic's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NurExone Biologic stock.
Last ReportedProjected for Next Year
Net Loss-3.6 M-3.8 M
Net Loss-3.6 M-3.8 M
Net Loss is likely to drop to about (3.8 M) in 2024. Net Loss is likely to drop to about (3.8 M) in 2024.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

NurExone Biologic Company Net Income Analysis

NurExone Biologic's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

More About Net Income | All Equity Analysis

Current NurExone Biologic Net Income

    
  (3.64 M)  
Most of NurExone Biologic's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NurExone Biologic is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition

NurExone Net Interest Income

Net Interest Income

44,100

At this time, NurExone Biologic's Net Interest Income is fairly stable compared to the past year.
Based on the recorded statements, NurExone Biologic reported net income of (3.64 Million). This is 101.07% lower than that of the Biotechnology sector and 105.2% lower than that of the Health Care industry. The net income for all Canada stocks is 100.64% higher than that of the company.

NurExone Net Income Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NurExone Biologic's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NurExone Biologic could also be used in its relative valuation, which is a method of valuing NurExone Biologic by comparing valuation metrics of similar companies.
NurExone Biologic is currently under evaluation in net income category among its peers.

NurExone Fundamentals

About NurExone Biologic Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze NurExone Biologic's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NurExone Biologic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NurExone Biologic based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for NurExone Stock Analysis

When running NurExone Biologic's price analysis, check to measure NurExone Biologic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NurExone Biologic is operating at the current time. Most of NurExone Biologic's value examination focuses on studying past and present price action to predict the probability of NurExone Biologic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NurExone Biologic's price. Additionally, you may evaluate how the addition of NurExone Biologic to your portfolios can decrease your overall portfolio volatility.